Page 47 - 82_01

cardiac mechanical function. Cardiovasc Res 1995;
31995; 0:200–4.
156. Gourine AV, Gonon AT, Pernow J. Involvement of
nitric oxide in cardioprotective effect of endothelin
receptor antagonist during ischemia-reperfusion. Am J
Physiol Heart Circ Physiol 2001; 280 (3):H1105-12
157. Brunner F. Interaction of nitric oxide and endothelin-
1 in ischemia/reperfusion injury of rat heart. J Mol
Cell Cardiol 1997; 29 (9):2363-74.
158. Zhao YB, Wang YZ, Yue YH, Zhao WC, Feng GX.
Variation of plasma levels of endothelin, calcitonin
gene-related peptide, nitric oxide, and
malondialdehyde in acute myocardial ischemia
reperfusion injury in a rabbit model. Genet Mol Res
2015; 14 (2):5577-84.
159. Pabla R, Buda AJ, Flynn DM, Blessé SA, Shin AM,
Curtis MJ, Lefer DJ. Nitric oxide attenuates
neutrophil-mediated myocardial contractile
dysfunction after ischemia and reperfusion. Circ. Res
1996; 78: 65-72.
160. Matheis G, Sherman MP, Buckberg GD, Haybron
DM, Young HH, Ignarro. Role of L-arginine-nitric
oxide pathway in myocardial reoxygenation injury.
Am. J. Physiol. 1992; 262: 16-20.
161. Kawahara K, Hachiro T, Yokokawa T, Nakajima T,
Yamauchi Y, Nakayama Y. Ischemia/reperfusion-
induced death of cardiac myocytes: possible
involvement of nitric oxide in the coordination of
ATP supply and demand during ischemia. J Mol Cell
Cardiol 2006; 40 (1):35-46.
162. Jones SP, Hoffmeyer MR, Sharp BR, Ho YS, Lefer
DJ Jones SP, Hoffmeyer MR, Sharp BR, Ho YS,
Lefer DJ. Role of intracellular antioxidant enzymes
after in vivo myocardial ischemia and reperfusion. Am
J Physiol Heart Circ Physiol 2003: 284: H277–82
163. Khan IA. Role of endothelin-1 in acute myocardial
infarction. Chest 2005; 127: 1474-6.
164. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia
D, Burzotta F, Trani C, Mazzari MA, Mongiardo R,
De Vita M, Rebuzzi AG, Lüscher TF, Crea F.
Endothelin-1 and acutemyocardial infarction: a no-
reflow mediator after successfulpercutaneous
myocardial revascularization. Eur Heart J 2006; 27:
1793-8.
165. Adlbrecht C, Bonderman D, Plass C, Jakowitsch J,
Beran G, Sperker W, Siostrzonek P, Glogar D, Maurer
G, Lang IM. Active endothelin is an important
vasoconstrictor in acute coronary thrombi. Thromb
Haemost. 2007; 97 (4):642-9.
166. Kolettis T, Barton M, Langleben D. Endothelin in
coronary artery disease and Myocardial Infarction.
Cardiology in Review 2013; 21 (5):249–56.
167. Omland T, Lie RT, Aakvaag A, Aarsland T,
Dickstein K. Plasma endothelin determination as a
prognostic indicator of 1-year mortality afteracute
myocardial infarction. Circulation 1994; 89: 1573-
1579. 166-205.
46
Godofredo Diéguez Castrillo
168. Yip HK, Wu CJ, Chang HW, Yang CH, Yu TH, Chen
YH, Hang CL. Prognostic value of circulating levels
of endothelin-1 in patients after acute myocardial
infarction undergoing primary coronary angioplasty.
Chest 2005; 127:1491–7.
169. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia
D, Burzotta F, Trani C, Mazzari MA, Mongiardo R,
De Vita M, Rebuzzi AG, Lüscher TF, Crea F.
Endothelin-1and acute myocardial infarction: a no-
reflow mediator after successful percutaneous
myocardial revascularization. Eur Heart J2006;
27:1793–8.
170. Eitel I, Nowak M, Stehl C, Adams V, Fuernau G,
Hildebrand L, Desch S, MD, Schuler G, Thiele H.
Endothelin-1release in acute myocardial infarction as
a predictor of long-term prognosis and no-reflow
assessed by contrast-enhanced magnetic resonance
imaging. Am Heart J 2010;159:882–90.
171. Freixa X, Heras M, Ortiz JT, Argiró S, Guasch E,
Doltra A, Jiménez M, Betriua A, Masottia M.
Usefulness of Endothelin-1 Assessment in Acute
Myocardial Infarction Rev Esp Cardiol 2011;64
(2):105-10.
172. Yang Z, Li J, Kong J, Wu S. Impairment of vascular
endothelial function following reperfusion therapy in
patients with acute myocardial infarction Int Med Res
2013; 41 (4):1074-8.
173. Kilickesmez KO, Bingöl G, Bulut L, Sinan UY,
Abaci O, Ersanli M, Gurmen T. Relationship between
serum endothelin-1 level and spontaneous reperfusion
in patients with acute myocardial infarction. Coron
Artery Di 2015;. 26 (1):37-41.
174. Cao L, Huang C, Huang N, Li J. ET-1/NO: A
controversial Target for Myocardial Ischemia-
Reperfusuion Injury. Cardiology 2014; 17 (2):140;
Letter to Editor
175. Wainwright CL, McCabe C, Kane KA. Endothelin
and the ischaemic heart. Curr Vasc Pharmacol 2005; 3
(4):333-4.
176. Tsutamoto T, Wada A, Hayashi M, Tsutsui T, Maeda
K, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T,
Takayama T, Ishii C, Kinoshita M. Relationship
between transcardiac gradient of endothelin-1 and left
ventricular remodeling in patients with first anterior
myocardial infarction. Eur Heart J 2003; 24: 346-55.
177. Maulik N, Engelman DT, Watanabe M, Engelman
RM, Maulik G, Cordis GA, Das DK. Nitric oxide
signaling in ischemic heart. Cardiovasc Res1995;
30:593–601.
178. Lefer, A. M. Attenuation of myocardial ischemia–
reperfusion injury with nitric oxide replacement
therapy. Ann Thorac Surg1995; 60, 847–51.
179. Schulz R, Wambolt R. Inhibition of nitric oxide
synthesis protects the isolated working rabbit heart
from ischaemia–reperfusion injury. Cardiovasc
Res1995; 30:432–39.
180. Thompson M, Westwick J, Woodward B. Responses
@Real Academia Nacional de Farmacia. Spain